ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1002

Nerve and Airway-associated Tissue Resident Pulmonary Macrophages Limit Infiltration and Alter Phenotype of Infiltrating Monocytes and Fibrocytes to Reduce Pulmonary Fibrosis
Abstract Number: 1003

Significant Enrichment of Pathogenic CD206+CD163+ Macrophages in Rheumatoid Arthritis Synovial Tissue with Distinct Transcriptional Signatures
Abstract Number: 1004

Manipulation of B7 Family Member Expression Demonstrates Synovial Macrophage Plasticity and Possible Future Targets for Treatment of Rheumatoid Arthritis
Abstract Number: 1005

CD209/CD14+ Dendritic Cells Characterization in Rheumatoid and Psoriatic Arthritis Patients: Activation, Synovial Infiltration and Therapeutic Targeting
Abstract Number: 1006

MAA Modified and/or Citrullinated Proteins Stimulate Macrophages and Human Fibroblast-Like Synoviocytes to Increase the Secretion/Expression of Fractalkine Ligand (CX3CL1) and Fractalkine Receptor (CX3CR1)
Abstract Number: 1007

Vascular Deposition of Oxidized LDL Is Increased in Children with Untreated Juvenile Dermatomyositis
Abstract Number: 1008

Synovial Fluid IL-36γ in Patients with Enthesitis Related Arthritis (ERA) Correlates with Disease Activity and Leads to Production of IL-6 by Fibroblast Like Synoviocytes
Abstract Number: 1009

Expanded B Cell-Helper T Cells in ANA+ Oligoarticular Juvenile Idiopathic Arthritis
Abstract Number: 1010

Proton Pump Inhibitors Suppress IL-1 Mediated Carditis in a Murine Model of Kawasaki Disease
Abstract Number: 1011

Validation of Bioinformatics Pipeline to Detect NEMO-Deleted Exon 5 Autoinflammatory Syndrome (NEMO-NDAS) and Preliminary Clinical and Immunologic Characterization
Abstract Number: 1012

Altered T Cell Responses, and Synergistic Regulation of Synovial Fibroblasts Function in Children with Down’s Syndrome-Associated Arthritis
Abstract Number: 1013

SARS-CoV-2 Antibody Phenotype and Immune Gene Expression in Multi-system Inflammatory Syndrome in Children
Abstract Number: 1014

Enhanced Expression of Rheumatoid Arthritis Related Autoantibodies Following Airborne Endotoxin Exposure in the Setting of Collagen-Induced Arthritis
Abstract Number: 1015

Preclinical Investigation of the First-in-Class SIK2/SIK3 Inhibitor GLPG3970 in Models of Arthritis
Abstract Number: 1016

Assessment of Pre-Inflammatory Mesenchymal (PRIME) Cells as a Biomarker of Tumor Necrosis Factor-Induced Arthritis in Mice

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].